Cisplatin news

All news on Cisplatin (also known as Cis-diamminedichloroplatinum(II) and Platinol): plants, production capacities, investments and involved companies.

29 October 2025
Merck's KEYTRUDA Approved in EU for Treating Resectable LA-HNSCC
KEYTRUDA gains EU approval as the first anti-PD-1 therapy for resectable LA-HNSCC with PD-L1 expression, based on KEYNOTE-689 results.
23 October 2025
Merck's KEYTRUDA and KEYTRUDA QLEX Get FDA Priority Review for Bladder Cancer Treatment
FDA grants priority review for KEYTRUDA combinations with Padcev, showing improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy.
20 October 2025
Johnson & Johnson's INLEXZO™ and Cetrelimab Show Promising Pre-Surgical Results in Bladder Cancer
Phase 2b study shows INLEXZO™ plus cetrelimab achieves significant pathologic response rates in muscle invasive bladder cancer patients ineligible for platinum-based chemotherapy.
19 October 2025
Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer
Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.
18 October 2025
Merck: KEYTRUDA and Padcev Cut Bladder Cancer Risks Pre- and Post-Surgery
KEYTRUDA and Padcev improve survival rates in muscle-invasive bladder cancer patients ineligible for cisplatin, showing significant event-free and overall survival benefits.
19 September 2025
Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use
CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.

Who will be producing Cisplatin in the future?

Find out with chemXplore Analytics